Quantitative CT assessment of bronchial and vascular alterations in severe precapillary pulmonary hypertension.
Aged
Airway Remodeling
Arterial Pressure
Bronchi
/ diagnostic imaging
Computed Tomography Angiography
Decision Support Techniques
Familial Primary Pulmonary Hypertension
/ diagnostic imaging
Female
Humans
Male
Middle Aged
Oxygen
/ blood
Partial Pressure
Predictive Value of Tests
Prognosis
Pulmonary Artery
/ diagnostic imaging
Pulmonary Disease, Chronic Obstructive
/ complications
Retrospective Studies
Risk Factors
Severity of Illness Index
Thromboembolism
/ complications
Vascular Remodeling
COPD
computed tomography
prediction
pulmonary hypertension
quantitative
Journal
International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481
Informations de publication
Date de publication:
Historique:
entrez:
28
2
2019
pubmed:
28
2
2019
medline:
30
7
2019
Statut:
epublish
Résumé
Little is known about in vivo alterations at bronchial and vascular levels in severe pulmonary hypertension (PH) of different etiologies. We aimed to compare quantitative computed tomography (CT) data from the following three groups of severe precapillary PH patients: COPD, idiopathic pulmonary arterial hypertension (iPAH), and chronic thromboembolic PH (CTEPH). This study was approved by the institutional review board. Severe PH patients (mean pulmonary arterial pressure [mPAP] ≥35 mmHg) with COPD, iPAH, or CTEPH (n=24, 16, or 16, respectively) were included retrospectively between January 2008 and January 2017. Univariate analysis of mPAP was performed in each severe PH group. Bronchial wall thickness (WT) and percentage of cross sectional area of pulmonary vessels less than 5 mm WT was higher and %CSA Unlike in severe iPAH and CTEPH, severe PH with COPD can be predicted by "paw score" reflecting bronchial and vascular morphological differential alterations.
Sections du résumé
BACKGROUND
BACKGROUND
Little is known about in vivo alterations at bronchial and vascular levels in severe pulmonary hypertension (PH) of different etiologies. We aimed to compare quantitative computed tomography (CT) data from the following three groups of severe precapillary PH patients: COPD, idiopathic pulmonary arterial hypertension (iPAH), and chronic thromboembolic PH (CTEPH).
PATIENTS AND METHODS
METHODS
This study was approved by the institutional review board. Severe PH patients (mean pulmonary arterial pressure [mPAP] ≥35 mmHg) with COPD, iPAH, or CTEPH (n=24, 16, or 16, respectively) were included retrospectively between January 2008 and January 2017. Univariate analysis of mPAP was performed in each severe PH group. Bronchial wall thickness (WT) and percentage of cross sectional area of pulmonary vessels less than 5 mm
RESULTS
RESULTS
WT was higher and %CSA
CONCLUSION
CONCLUSIONS
Unlike in severe iPAH and CTEPH, severe PH with COPD can be predicted by "paw score" reflecting bronchial and vascular morphological differential alterations.
Identifiants
pubmed: 30809092
doi: 10.2147/COPD.S177638
pii: copd-14-381
pmc: PMC6377046
doi:
Substances chimiques
Oxygen
S88TT14065
Types de publication
Comparative Study
Journal Article
Observational Study
Langues
eng
Pagination
381-389Déclaration de conflit d'intérêts
Disclosure Berger reports personal fees, nonfinancial support from Novartis, Boehringer Ingelheim, AstraZeneca, and GSK outside the submitted work; in addition, he has a patent EP N°15152886.6, ie, new compositions and methods of treating and/or preventing COPD, which is pending. Laurent reports personal fees from Boehringer Ingelheim, Roche, Novartis, Bayer, Guerbet, and Chiesi outside the submitted work. Girodet reports personal fees and nonfinancial support from Novartis, Chiesi, Takeda, Boehringer Ingelheim, and AstraZeneca outside the submitted work. The other authors report no conflicts of interest in this work.
Références
Thorax. 2002 Jun;57(6):473-6
pubmed: 12037220
Am J Respir Crit Care Med. 2003 Mar 1;167(5):735-40
pubmed: 12480614
Eur Respir J. 2003 May;21(5):892-905
pubmed: 12765440
J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):40S-47S
pubmed: 15194177
Am J Respir Crit Care Med. 2005 Jul 15;172(2):189-94
pubmed: 15831842
Radiology. 2005 Jun;235(3):1055-64
pubmed: 15833982
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Eur Respir J. 2005 Sep;26(3):511-22
pubmed: 16135736
Circ Res. 2006 Sep 29;99(7):675-91
pubmed: 17008597
Radiology. 2007 Feb;242(2):563-72
pubmed: 17179398
Chest. 1991 Jan;99(1):112-20
pubmed: 1824624
Am J Respir Crit Care Med. 2009 Apr 1;179(7):615-21
pubmed: 19164700
Radiology. 2009 Dec;253(3):844-53
pubmed: 19789219
Acad Radiol. 2010 Jan;17(1):93-9
pubmed: 19796970
Am J Respir Crit Care Med. 2010 Feb 1;181(3):218-25
pubmed: 19875683
AJR Am J Roentgenol. 2011 Mar;196(3):524-32
pubmed: 21343493
Jpn J Radiol. 2011 May;29(4):251-5
pubmed: 21607838
Heart. 2012 Dec;98(24):1805-11
pubmed: 22760869
Eur Respir Rev. 2013 Dec;22(130):543-51
pubmed: 24293470
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16
pubmed: 24355635
Am J Respir Crit Care Med. 2015 Jan 1;191(1):63-70
pubmed: 25393421
Eur Respir J. 2015 Oct;46(4):903-75
pubmed: 26318161
Thorax. 2016 Sep;71(9):830-7
pubmed: 27084957
Pulm Circ. 2016 Mar;6(1):70-81
pubmed: 27162616
Int J Chron Obstruct Pulmon Dis. 2016 Jun 28;11:1435-45
pubmed: 27418816
Int J Chron Obstruct Pulmon Dis. 2016 Aug 22;11:1965-71
pubmed: 27578971
Thorax. 1987 Feb;42(2):131-5
pubmed: 3433237
Jpn Heart J. 1979 Jul;20(4):395-405
pubmed: 470138
J Pathol. 1983 Dec;141(4):441-7
pubmed: 6363654
N Engl J Med. 1996 Feb 1;334(5):296-301
pubmed: 8532025